Crossmark Global Holdings Inc. Increases Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM)

Crossmark Global Holdings Inc. grew its stake in HUTCHMED (China) Limited (NASDAQ:HCM) by 10.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,591 shares of the company’s stock after buying an additional 1,799 shares during the period. Crossmark Global Holdings Inc.’s holdings in HUTCHMED were worth $268,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Public Employees Retirement System of Ohio bought a new position in HUTCHMED in the third quarter worth about $35,000. Blue Trust Inc. raised its position in shares of HUTCHMED by 638.2% in the 3rd quarter. Blue Trust Inc. now owns 3,536 shares of the company’s stock worth $69,000 after acquiring an additional 3,057 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of HUTCHMED by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company’s stock valued at $117,000 after purchasing an additional 2,321 shares during the period. Rhumbline Advisers boosted its position in shares of HUTCHMED by 8.1% during the second quarter. Rhumbline Advisers now owns 7,553 shares of the company’s stock valued at $129,000 after purchasing an additional 564 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in HUTCHMED in the second quarter worth $213,000. Institutional investors own 8.82% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut shares of HUTCHMED from a “buy” rating to a “hold” rating in a research report on Monday, November 18th.

HUTCHMED Stock Performance

Shares of NASDAQ:HCM opened at $13.64 on Tuesday. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07. HUTCHMED has a 1-year low of $11.93 and a 1-year high of $21.92. The firm’s 50 day simple moving average is $15.56 and its two-hundred day simple moving average is $17.55.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.